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Abstract
Background: Glucocorticoids are potent anti-inflammatory agents commonly used to treat inflammatory diseases. They
convey signals through the intracellular glucocorticoid receptor (GR), which upon binding to ligands, associates with
genomic glucocorticoid response elements (GREs) to regulate transcription of associated genes. One mechanism by which
glucocorticoids inhibit inflammation is through induction of the dual specificity phosphatase-1 (DUSP1, a.k.a. mitogen-
activated protein kinase phosphatase-1, MKP-1) gene.
Methodology/Principal Findings: We found that glucocorticoids rapidly increased transcription of DUSP1 within 10
minutes in A549 human lung adenocarcinoma cells. Using chromatin immunoprecipitation (ChIP) scanning, we located a GR
binding region between 21421 and 21118 upstream of the DUSP1 transcription start site. This region is active in a reporter
system, and mutagenesis analyses identified a functional GRE located between 21337 and 21323. We found that
glucocorticoids increased DNase I hypersensitivity, reduced nucleosome density, and increased histone H3 and H4
acetylation within genomic regions surrounding the GRE. ChIP experiments showed that p300 was recruited to the DUSP1
GRE, and RNA interference experiments demonstrated that reduction of p300 decreased glucocorticoid-stimulated DUSP1
gene expression and histone H3 hyperacetylation. Furthermore, overexpression of p300 potentiated glucocorticoid-
stimulated activity of a reporter gene containing the DUSP1 GRE, and this coactivation effect was compromised when the
histone acetyltransferase domain was mutated. ChIP-reChIP experiments using GR followed by p300 antibodies showed
significant enrichment of the DUSP1 GRE upon glucocorticoid treatment, suggesting that GR and p300 are in the same
protein complex recruited to the DUSP1 GRE.
Conclusions/Significance: Our studies identified a functional GRE for the DUSP1 gene. Moreover, the transcriptional
activation of DUSP1 by glucocorticoids requires p300 and a rapid modification of the chromatin structure surrounding the
GRE. Overall, understanding the mechanism of glucocorticoid-induced DUSP1 gene transcription could provide insights into
therapeutic approaches against inflammatory diseases.
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Introduction
Glucocorticoids are steroid hormones that exhibit potent anti-
inflammatory effects through two main mechanisms. First, they
inhibit the transcription of proinflammatory genes, such as
cytokines, chemokines, and adhesion molecules via suppression
of the transcriptional activation induced by AP-1 and NFkB
[1,2,3,4,5]. Second, they induce genes that antagonize the
inflammatory response, including the glucocorticoid-induced
leucine zipper (GILZ) and dual specificity phosphatase-1 (DUSP1,
a.k.a. mitogen-activated protein kinase phosphatase-1, MKP-1,
Entrez GeneID: 1843) [6].
DUSP1 opposes the inflammatory response by blocking crucial
signaling pathways. DUSP1 is a member of a large family of
multifunctional phosphatases that resides in the nucleus and
specifically dephosphorylates and inactivates members of the
MAPK family, such as JNK, p38 MAPK, and ERK [7,8]. These
MAPKs play important roles in the stimulation of the inflamma-
tory response by increasing the expression of many proinflamma-
tory mediators [9,10]. For example, cytokines, such as tumor
necrosis factor a (TNF-a) and interleukin-1b (IL-1b), and
endotoxins, such as lipopolysaccharides, have been shown to
activate p38 MAPK, which in turn phosphorylates and activates
downstream MAPKAP kinase 2 (MK2) [11,12]. MK2 then
phosphorylates and inactivates ZFP36 (also known as tristetrapro-
lin, TTP). ZFP36 destabilizes the mRNA of many proinflamma-
tory genes by binding to an AU-rich element (ARE) located at the
39 untranslated region (UTR) of their mRNA [11,12]. Increased
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disrupts the signal leading to the induction of pro-inflammatory
gene expression.
Mouse knockout studies support this role. Macrophages isolated
from mice lacking DUSP1 gene (Dusp1
2/2) have prolonged
activation of JNK and p38 MAPK, resulting in overexpression of
inflammatory genes [13,14]. Similarly, in LPS-induced endotox-
emia and collagen-induced arthritis (experimental models of acute
or chronic inflammation, respectively), Dusp1
2/2 mice show
exaggerated inflammatory responses [15]. Lastly, in Dusp1
2/2
macrophages, the ability of glucocorticoids to inhibit the
expression of specific pro-inflammatory genes is significantly
compromised [15]. Overall, studies of various inflammatory
disease models with Dusp1
2/2 animals support the critical role
of DUSP1 in regulating anti-inflammatory responses mediated by
glucocorticoids [16,17,18].
Despite the importance of DUSP1 in glucocorticoid-regulated
inflammatory responses, how glucocorticoids regulate its expres-
sion is poorly understood [6,19]. Glucocorticoids act through the
intracellular glucocorticoid receptor (GR) to exert their biological
functions. GR is a transcriptional regulator, which, upon binding
to cognate ligands, occupies specific genomic regions called
glucocorticoid response elements (GREs) [20]. These GREs are
typically composite elements, composed of multiple cis-acting
elements that work in a combinatorial fashion to direct a complete
glucocorticoid response [21,22]. Among these cis-acting elements
are often multiple GR binding sites as well as binding sites for
other transcriptional regulators. As each of these GREs appear to
be different, it is likely that compositionally and/or conforma-
tionally distinct transcriptional regulatory complexes assemble at
each locus, resulting in distinct mechanisms of transcriptional
regulation at each GR target gene. As DUSP1 plays an important
role in mediating the anti-inflammatory response of glucocorti-
coids, dissecting the mechanisms by which GR activates DUSP1
gene transcription is critical for our fundamental understanding of
anti-inflammatory action exhibited by glucocorticoids. In this
report, we identified a GRE for the human DUSP1 gene. We also
analyzed the effect of glucocorticoids on the chromatin structure
and acetylation status of histones surrounding the GRE. Finally,
using RNA interference and chromatin immunoprecipitation
approaches, we identified a transcriptional cofactor participating
in GR-activated DUSP1 gene transcription.
Methods
Cell Culture
A549 cells (type II alveolar lung epithelium cells; ATCC
CCL85) [23] were cultured in DMEM (Cellgro) with 5% fetal
bovine serum (FBS; J R Scientific). When cells were treated with
dexamethasone (DEX, a synthetic glucocorticoid, Sigma) or
DMSO (vehicle control), DMEM with 5% charcoal stripped
FBS (J R Scientific) was used.
ChIP
A549 cells were grown to confluence and treated with 0.5 mM
DEX or DMSO, then cross-linked by using formaldehyde at a
final concentration of 1% at room temperature for 5 minutes. The
ChIP protocols were otherwise as previously described [24,25].
ChIP-reChIP
A549 cells were grown to confluence (46150 mm plates per
treatment) and treated with 0.5 mM DEX or DMSO, then cross-
linked by using formaldehyde at a final concentration of 1% at
room temperature for 5 minutes. Reactions were quenched with
0.125 M glycine for 5 min. Cells were washed with PBS, scraped
in cell lysis buffer (50 mM HEPES-KOH at pH 7.4, 1 mM
EDTA, 150 mM NaCl, 10% glycerol, 0.5% Triton X-100)
supplemented with protease inhibitor cocktails (Calbiochem),
and incubated for 10 min at 4uC. Crude nuclei were collected
by centrifugation at 600 x g for 5 min at 4uC then resuspended in
1.5 ml of ice-cold RIPA buffer (10 mM Tris-HCL at pH 8.0,
1 mM EDTA, 150 mM NaCl, 5% glycerol, 1% Triton X-100,
0.1% sodium deoxycholate, 0.1% SDS, supplemented with
protease inhibitor). Chromatin was fragmented with 18 pulses of
20 sec at 30% power with a Branson Sonifier 250 sonicator at
4uC. To remove insoluble components, samples were centrifuged
at 13,000 rpm for 15 min at 4uC, and the supernatant was
recovered.
For the first round of IP, two aliquots from each treatment were
taken. 8 mg of rabbit polyclonal GR (N499) antibody was used to
immunoprecipitate GR-bound chromatin or 8 mg of rabbit
polyclonal IgG was used as a control for each aliquot, per
treatment. The samples rotated overnight at 4uC. 120 ml of 50%
protein A/G plus-agarose bead slurry (Santa Cruz Biotechnology)
was then added to each immunoprecipitation and rotated for 2 h
at 4uC. After incubation, beads were washed with 1 ml of solution
per wash as follows: twice with RIPA, twice with RIPA containing
510 mM NaCl, twice with LiCl buffer (20 mM Tris at pH 8.0,
1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% sodiumdeox-
ycholate), and twice with TE. Between each wash, samples were
rotated at room temperature for 5 min, followed by 1 min
centrifugation at 5,000 rpm. All washes were supplemented with
protease inhibitors. Immmunocomplexes were eluted by adding
75 ml TE with 10 mM DTT and incubated at 37uC for 30 min.
The samples were centrifuged at 800 x g for 2 minutes at room
temperature, and the supernatant was transferred to a clean
1.5 ml tube. An additional 14 ml of RIPA was added to dilute the
sample.
For the second round of IP, 8 mg of p300 (rabbit polyclonal,
Santa Cruz Biotechnology) was used in all samples and rotated
overnight at 4uC. Again, we added 120 ml of 50% protein A/G
plus-agarose bead slurry and washed as described, modified only
by replacing the final two TE washes with one wash in RIPA
buffer. After removing the last wash buffer, 75 ml of proteinase K
solution (TE pH 8.0, 0.7% SDS, 200 mg/ml proteinase K) was
added to each IP. Reactions were incubated for 3 h at 55uC, then
overnight at 65uC to reverse formaldehyde cross-links. DNA was
purified using a QIAquick PCR purification kit (Qiagen) and
eluted in 60 ml of Elution Buffer (Qiagen).
Transfection
To transfect A549 cells, we used Lipofectamine 2000 (Invitro-
gen) according to the technical manual in the 24-well format.
Twenty-four hours post-transfection, cells were treated with either
DMSO or 0.5 mM DEX for 18–24 h. Cells were then harvested,
and luciferase activity was measured by a Dual-Luciferase
Reporter Assay kit (Promega) according to the technical manual.
pCI-p300 wild type and pCI-p300DHAT were provided by Mike
Stallcup (USC) [26].
Cloning and Site Directed Mutagenesis
The human DUSP1 genomic region containing the predicted
GR binding site was amplified by PCR using specific primers. The
PCR fragment was restriction-digested and subcloned into the
pGL4-TATA reporter. A mutagenesis kit (QuikChange) was used
to make site-directed mutations per the manufacturer’s instruc-
tions (Stratagene).
Glucocorticoid-Induced DUSP1
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A549 cells were grown to confluence in 6-well plates then
treated with DMSO or 0.5 mM DEX for 10 min. Cells were
washed then scraped in 1 ml ice cold DNase I Buffer + NP40
(20 mM HEPES pH 7.4, 0.5 mM CaCl2, 5% glycerol, 3 mM
MgCl2, 0.2 mM spermine, 0.2 mM spermidine, 0.2% NP40).
Cells were vortexed for 10 seconds to homogenize, then
centrifuged at 500 x g in a microfuge for 5 minutes at 4uC.
Pellets were resuspended in 100 ml DNase I Buffer without NP40,
then equilibrated to room temperature for 10 min. Samples were
digested with 5 units of DNase I (QIAGEN) for 5 minutes at 37uC,
and reactions were stopped by addition of equal volume (100 ml)
26 Stop Reaction Buffer (50 mM Tris-HCl pH 8.0, 1% SDS,
200 mM NaCl, 12.5 mM EDTA) with 200 mg/ml Proteinase K,
and incubated at 65uC for 4 hours or overnight. DNA was purified
using a PCR purification kit (QIAGEN), and samples were
measured and diluted to use 50 ng/well for qPCR analysis.
RNA interference (RNAi)
p300 (QIAGEN), CBP (Santa Cruz Biotechnology), and a
scramble sequence (control, QIAGEN) were reverse transfected
with HiPerFect transfection reagent (QIAGEN) according to the
technical manual. For gene expression analyses, reverse transfec-
tion was done in a 24-well plate. Forty-eight hours post-
transfection, cells were treated with either DMSO or 0.5 mM
DEX for 5 hours, and total RNA was then isolated. For western
blot analyses, cells were collected from a 24-well plate 48 hours
post-transfection. For ChIP experiments, reverse transfection was
done in 10 cm plates. Again, 48 hours post-transfection, cells were
treated with either DMSO or 0.5 mM DEX, this time for 10
minutes.
Western Blot
A549 cells transfected with p300, CBP, or scramble (control)
siRNA were collected 48 hours post-transfection in RIPA buffer
(10 mM Tris-HCl pH 8.0, 1 mM EDTA, 150 mM NaCl, 5%
glycerol, 0.1% sodium deoxycholate, 0.1% SDS, 1% Triton X-
100, supplemented with protease inhibitors). Proteins were
resolved and imaged as described [27. The following antibodies
were used: p300 rabbit polyclonal IgG (sc-584; Santa Cruz
Biotechnology), CBP mouse monoclonal IgG1 (sc-7300, Santa
Cruz Biotechnology), b-Actin (C4) mouse monoclonal IgG1 (sc-
47778; Santa Cruz Biotechnology), anti-rabbit IgG1-HRP (Cell
Signaling), and anti-mouse IgG1-HRP (sc-2060; Santa Cruz
Biotechnology).
Micrococcal Nuclease (MNase)
A549 cells were grown to confluence and treated with DMSO
or 0.5 mM DEX for 10 minutes. Cells were cross-linked with 1%
formaldehyde for 3 minutes at 22uC, and reactions were quenched
by adding glycine to a final concentration of 0.125 M. Cells were
then rinsed in PBS and scraped in ice-cold MNase NP-40 Lysis
Buffer (10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5%
NP-40, 0.15 mM spermine, 0.5 mM spermidine). Cells were
vortexed for 10 seconds to ensure thorough lysis before nuclei were
collected by centrifugation at maximal speed in a microfuge for 5
minutes at 4uC. Nuclei were washed in ice-cold MNase Digestion
Buffer without CaCl2 (10 mM Tris pH 7.4, 15 mM NaCl, 60 mM
KCl, 0.15 mM spermine, 0.5 mM spermidine) and re-centrifuged.
Pelleted nuclei were suspended in ice-cold MNase Digestion Buffer
with CaCl2 (10 mM Tris pH 7.4, 15 mM NaCl, 60 mM KCl,
0.15 mM spermine, 0.5 mM spermidine, 1 mM CaCl2). Samples
were treated with 1 unit of MNase (Nuclease micrococcal from
Staphylococcus aureus, Sigma-Aldrich, N5386-200UN) for 10
minutes at 25uC. Reactions were stopped by addition of 80 ml
MNase Digestion Buffer with CaCl2,2 0ml MNase Stop Buffer
(100 mM EDTA, 10 mM EGTA), 75 mg Proteinase K, and 20 ml
10% SDS, and incubated at 65uC for 4 hours or overnight.
Samples were then column purified using a PCR purification kit
(QIAGEN). RNaseA (Millipore) was diluted to 0.1 mg/ml in TE,
and 20 units were added to each sample for 2 hours at 37uC.
Samples were then purified using a PCR purification kit
(QIAGEN) and run on a 1.5% agarose gel. DNA fragments of
150 bp were purified using a gel extraction kit (QIAGEN).
Quantitative real-time PCR was used to measure the amount of
distinct genomic fragments surrounding the DUSP1 GRE. For
each primer set, a standard curve was generated using 1 mg,
0.25 mg, 0.0625 mg, and 0.015625 mg of human genomic DNA.
The amount of a particular genomic fragment in the MNase
sample was then calculated based on the standard curve.
Nuclear Run-on
A549 cells were grown to confluence and treated with DMSO
or 0.5 mM DEX for different times. Cells were then harvested and
incubated in lysis buffer (10 mM Tris-HCl pH 7.4, 3 mM MgCl2,
10 mM NaCl, 150 mM sucrose and 0.5% NP40) at 4uC for 5
minutes. Nuclei were then isolated by centrifugation at 170 x g at
4uC for 5 min. The total nuclei from each of the DMSO or DEX
treated samples were counted, and equal numbers of nuclei were
used for in vitro transcription. The samples were split into two
aliquots. One was incubated in 100 ml2 6 in vitro transcription
buffer (200 mM KCl, 20 mM Tris-HCl pH 8.0, 5 mM MgCl2,
4 mM dithiothreitol (DTT), 4 mM each of ATP, GTP and CTP,
200 mM sucrose and 20% glycerol) plus 8 ml biotin-UTP (Roche),
and the other in 100 ml2 6 in vitro transcription buffer plus 8 ml
UTP (negative control) for 30 minutes at 29uC. 6 ml of 250 mM
CaCl2 and 6 ml of RNAse free DNase (Roche) (10 U/ml) were then
added to stop the reactions. Total RNA was then isolated using
Nucleospin RNA II (Macherey-Nagel).
Dyna beads M-280 (Invitrogen) were washed twice in solution A
(0.1 mM NaOH, 0.5 M NaCl) for 5 min, once in solution B
(0.1 M NaCl) for 5 min, and then resuspended in binding/wash
buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA and 2 M NaCl)
plus 1 ml (40 U) RNasin per 100 ml of beads. 50 ml of beads (in
binding/wash buffer) were then added to RNA, incubated at 42uC
for 20 min, and then shaken for 2 h at room temperature.
Afterward, the beads were isolated and the supernatant discarded.
The beads were then washed once (5 min) with 500 ml 15%
formamide plus 26saline-sodium citrate (SSC) buffer, twice with
1m l2 6SSC buffer, then resuspended in 30 ml RNase and DNase
free water. 10 ml of beads were used for each reverse transcription
(RT) reaction prior to qPCR.
RNA, RT, qPCR
Total RNA was isolated from cells by using QIAshredder and
RNeasy kits (Qiagen) or a NucleoSpin RNAII kit (Macherey-
Nagel). To synthesize random-primed cDNA, 0.5 mg of total RNA
(10 ml), 4 ml of 2.5 mM dNTP, and 2 ml of random primers (New
England Biolabs) were mixed and incubated at 70uC for 10 min. A
4-ml cocktail containing 25 U of Moloney Murine Leukemia Virus
(M-MuLV) Reverse Transcriptase (New England Biolabs), 10 units
of RNasin (Promega), and 2 mlo f1 0 6 reaction buffer (New
England Biolabs) was then added. The reaction was incubated at
42uC for 1 h, then 95uC for 5 min.
The resultant cDNA was diluted to 200 ml with water, and
2.5 ml was used to perform qPCR using EVA QPCR SuperMix
Kit (Biochain) per the manufacturer’s protocol. qPCR was
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System (Applied Biosystems) and analyzed by using the nn-Ct
method as supplied by the manufacturer (Applied Biosystems).
Rpl19 expression was used for internal normalization. All primer
sequences are presented in Table S1.
Results
Induction of DUSP1 gene transcription by
glucocorticoids in human A549 cells
Previous studies have shown that DUSP1 gene expression is
induced by glucocorticoids in A549 cells [28]. To confirm that the
DUSP1 gene is a direct target of GR and to determine the kinetics
of glucocorticoid-induced transcription, we performed nuclear
run-on experiments. We isolated nuclei from A549 cells that were
treated with the synthetic glucocorticoid dexamethasone (DEX)
for 10, 30, and 90 minutes. Nascent transcripts from these nuclei
were labeled with biotin-UTP, and then isolated using magnetic
beads. After random-primed cDNA was synthesized, qPCR was
performed to measure the change of transcript levels using DUSP1
specific primers. As shown in Fig. 1A, transcription of DUSP1 is
induced rapidly, increasing approximately two fold after just 10
minutes of DEX treatment (compared to 90 minutes DMSO-
treated samples and no treatment), with levels continuing to
increase after 30 and 90 minutes (Fig. 1A). These results
demonstrate that glucocorticoids rapidly initiate transcription of
DUSP1, and that it is likely directly regulated by GR.
Identification of GREs in the human DUSP1 gene
As our data revealed that glucocorticoids stimulate DUSP1
through transcriptional initiation, we wished to further probe the
mechanism by which GR induces DUSP1 transcription. To this
end, we used a chromatin immunoprecipitation (ChIP) scanning
approach [23] to systematically locate the GR binding regions in
the vicinity of the human DUSP1 transcription start site (TSS).
A549 cells were treated with DMSO or DEX for 10 minutes,
when we first observed transcriptional initiation, then subjected to
a standard ChIP procedure [25] of formaldehyde cross-linking of
A549 cells, shearing of chromatin to approximately 200–500 bp
fragments, and precipitating cross-linked GR:DNA complexes
with GR-specific antibody. IgG antibody was used as a negative
control for all ChIP experiments. We performed qPCR on the
precipitated DNA fragments using six pairs of oligonucleotide
primers that amplify approximately 100 bp segments (Fig. 1B),
spaced at 300–500 bp intervals. As the average size of the sheared
DNA fragments is 300–500 bp, this arrangement of amplified
sequences can scan effectively for GR occupancy in the first 2 kb
upstream of the DUSP1 TSS. We found that two primer pairs,
flanking 21421 to 21333 and 21191 to 21118 respectively,
exhibited significant enrichment in GR ChIP (Fig. 1B), but not
with IgG alone (data not shown). These results reveal that GR
binding localizes between 21421 and 21118 of the TSS.
We next tested whether this GR binding region was a mediator
of glucocorticoid response. We subcloned the genomic region
extending approximately 200–300 bp upstream and downstream
of our ChIP fragments (21672 to 2959) into an E4 TATA box
containing pGL4 luciferase reporter to test whether the identified
GR-binding regions are glucocorticoid-responsive (Fig. 1C). We
transfected this reporter plasmid (pDUSP1) along with an
expression vector encoding human GR cDNA into A549 cells.
After 24 hours, cells were treated with DMSO or DEX for 18 to
20 hours. Cells were then lysed, and firefly luciferase assay was
performed. We found that firefly luciferase activity in DEX-treated
cell lysates was significantly higher than that of DMSO-treated cell
Figure 1. Identification of DNA elements mediating glucocor-
ticoid response in the human DUSP1 gene. A A549 cells were
untreated, treated with DMSO for 90 min, or treated with DEX (0.5 mM)
for 10 min, 30 min, and 90 min as shown. Nuclei were used for nuclear
run-on experiments with biotin-UTP to monitor in vitro transcription.
Newly synthesized RNA was isolated and used to make cDNA. qPCR was
performed to monitor changes in transcription rates using primers
specific to Dusp1 and Rpl19 (control). Data represent the standard error
mean (SEM) of the fold induction (DMSO- or DEX-treated cells divided
by untreated cells) from at least three experiments. B Identification of
GR binding regions in human DUSP1 using ChIP scanning across the
first 2 kb of the human DUSP1 promoter. A549 cells were treated with
DMSO or DEX (0.5 mM) for 10 min, and ChIP was performed with GR-
specific antibody as described. DUSP1 gene schematic shows the
location of six primers used (black boxes labeled p1-p6) for qPCR
analyses. The regions of the DUSP1 gene (relative to the TSS) amplified
by these primers are: p1 (21815 to 21717), p2 (21421 to 21333), p3
(21191 to 21118), p4 (2662 to 2543), p5 (2160 to 254), and p6 (+98
to +215). Data represent the SEM of the fold enrichment (DEX-treated
cells divided by DMSO-treated cells) from at least three experiments. C
DUSP1 GR binding region mediates glucocorticoid response. 21672 to
2959 (relative to the TSS) of the human DUSP1 genomic region was
subcloned into pGL4-TATA reporter plasmid to create pDUSP1. pDUSP1
was transfected into A549 cells along with an expression vector for
human GR. 24 h post-transfection, cells were treated with DMSO or DEX
(0.5 mM) for 18–20 h. Luciferase assay data represents the SEM of the
fold induction of luciferase activity (DEX-treated cells divided by DMSO-
treated cells) from at least three experiments.
doi:10.1371/journal.pone.0013754.g001
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region of the DUSP1 gene promoter is a functional GRE.
To further resolve binding in this region, we looked for direct
GR binding sites by searching for a consensus GR binding
sequence. Based on a compilation of known GR binding
sequences (S. Cooper and K. Yamamoto, unpublished data), we
searched for motifs matching the loose consensus sequence
XGXACXxxxXGTXCX. We identified a 15 bp sequence that
closely matched this consensus GRE in the 21672 to 2959 region
of the human DUSP1 promoter (GLS2). The search yielded four
more degenerate potential binding sites (GLS 1, 3, 4, 5, Fig. 2A).
To gauge the importance of each GLS to GRE activity, we
compared the wild type sequence to ones mutated at each of the
GLSs at position 5, where GR makes direct contact and is critical
for specific binding [29]. We transfected these mutant constructs
into A549 cells and found that mutating GLS2 (pDUSP1m2)
severely reduced the glucocorticoid response, whereas a mutation
at GLS5 (pDUSP1m5) had no effect (Fig. 2B). Mutations at GLS1,
GLS3, and GLS4 (pDUSP1m1, pDUSP1m3, pDUSP1m4)
showed a modest reduction of glucocorticoid response (Fig. 2B).
To verify the contribution of these sites, we performed double
mutations of GLS1 and GLS3 (pDUSP1m1m3), GLS1 and
GLS4 (pDUSP1m1m4), and GLS3 and GLS4 (pDUSP1m3m4).
These double mutations did not further compromise DEX
response, nor did the triple mutant (GLS1, GLS3 and GLS4,
pDUSP1m1m3m4). In all cases, the response of multiple
mutations to DEX was similar to single mutations within GLS1,
GLS3, and GLS4 (Fig. 2B). Overall, this mutational analysis
indicates that GLS2, which best fits the canonical GRE consensus,
is essential for conferring glucocorticoid response, whereas GLSs
Figure 2. Mutational analyses of GRE-like sequences (GLS) in the DUSP1 gene. A Five GLSs identified in the 21672 to 2959 region of the
human DUSP1 promoter. The locations of five GRE like sequences are: GLS1 (21382 to 21368), GLS2 (21337 to 21323), GLS3 (21254 to 21240),
GLS4 (21154 to 21140), GLS5 (21030 to 21018). The position of each nucleotide in each GLS is indicated. The specific point mutations made in each
GLS are shown in red. In GLS1-GLS4, position 5 was mutated from C to A. In GLS5, position 5 was mutated from C to G. The consensus GR binding
sequence is indicated in blue. B Wild type and mutant reporter plasmids were transfected into A549 cells along with a human GR expression vector.
24 h post-transfection, cells were treated with DMSO or DEX (0.5 mM) for 18–20 h. Luciferase assay data represent the SEM of the fold induction of
luciferase activity (DEX-treated cells divided by DMSO-treated cells) from at least three experiments. Results are shown as a percent of wild type
DUSP1 response. For mutant plasmids, the mutation at distinct GLSs is indicated (e.g. m1 indicates a mutation at GLS1).
doi:10.1371/journal.pone.0013754.g002
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that could contribute to hormone response under some conditions.
GRE containing GLS2 has active response element
chromatin marks
To further understand the mechanisms underlying glucocorti-
coid-regulated DUSP1 gene transcription, we investigated the
effects of glucocorticoids on the chromatin structure of the DUSP1
gene. Chromatin architecture plays a critical role in the control of
eukaryotic gene transcription in vivo because it determines the
accessibility of genomic regulatory sequences to the transcriptional
machinery. Based on their sensitivity to cleavage when intact
nuclei are exposed to DNA-modifying agents, such as endonucle-
ase DNase I, we can analyze the accessibility of the chromatin
structure of specific genomic regions.
We first tested whether glucocorticoids affect DNase I
accessibility within the DUSP1 promoter. Nuclei from A549 cells
treated with DMSO or DEX for 10 minutes were subject to
cleavage by DNase I for 5 minutes. DNA fragments were then
isolated and analyzed with qPCR using primers from the
previously described ChIP experiments. We found that the region
from 22000 to +1 (TSS) of DUSP1 was already sensitive to DNase
I before DEX treatment (compared to DNA not digested by
DNase I, Fig. 3A). In contrast, the promoter region of a-
fetoprotein, a liver-specific gene not expressed in A549 cells, was
sensitive neither to DNase I digestion nor DEX treatment (Fig.
S1). With DUSP1, DEX treatment markedly increased DNase I
accessibility in all areas examined except 2160 to 264 (Fig. 3A),
which was already very sensitive to DNase I prior to DEX
treatment (Fig. 3A). These results indicate that DEX treatment
and GR binding can further ‘‘open up’’ the chromatin structure of
most genomic regions surrounding the DUSP1 promoter.
This opening of chromatin within the GRE suggests that
nucleosomes have been repositioned or remodeled. Glucocorti-
coids have previously been shown to induce chromatin remodel-
ing; thus, they must either disrupt a nucleosome assembly or
change the position of nucleosomes in the genome (41). To test
this, we used MNase to map the position of nucleosomes
surrounding the DUSP1 gene. We treated A549 cells with DMSO
or DEX for 10 min. Nuclei were isolated, cross-linked with
formaldehyde, and digested with MNase. The MNase sensitivity of
the chromatin was then analyzed using qPCR with primers
designed to anneal to the DNA approximately every 50 bp from
21550 to 21050 of the DUSP1 TSS. Because the nucleosomal
regions are less accessible to MNase, we recovered more DNA
fragments from these regions. In contrast, the recovery of DNA
fragments from linker regions was lower, as most of these
fragments were digested by MNase. In untreated cells, three solid
nucleosome positions are evident: from 21500 to 21350
(nucleosome 1), 21350 to 21200 (nucleosome 2), and 21200 to
21050 (nucleosome 3) (Fig. 3B). Consistent with our DNase
sensitivity assay, addition of DEX appeared to increase the
sensitivity to MNase in nucleosomes 1 and 2 (Fig. 3B). These data
indicate that a glucocorticoid-dependent remodeling of chromatin
structure within the DUSP1 GRE is associated with gene
activation.
Glucocorticoids increase histone H3 and H4 acetylation
of the DUSP1 gene promoter
An increase in the acetylation of histones H3 and H4 has been
correlated with both gene transcription and active DNA control
elements such as response elements and enhancers [30]. We
treated A549 cells for 10 minutes with DMSO or DEX, then
performed ChIP experiments using antibodies that recognize
multiple acetyl lysines in the tails of either histone H3 (AcH3) or
H4 (AcH4) to examine whether glucocorticoids affect the overall
histone acetylation status of the DUSP1 gene promoter. Total H3
and H4 levels were also monitored by ChIP, as the levels of AcH3
and AcH4 are associated with the overall density of histone in each
genomic region. Thus, the ratio of AcH3/H3 or AcH4/H4
accurately reflects the change of histone acetylation. In compar-
ison to ChIP done with control IgG antibodies, we found that
AcH3/H3 and AcH4/H4 levels were already enriched before
DEX treatment in all genomic regions tested (Fig. S2). These
results indicate that the 22000 to +1 region of the DUSP1 gene
was already acetylated before DEX treatment. DEX treatment
Figure 3. DUSP1 DNaseI accessibility and nucleosome mapping
in response to glucocorticoids. A DNase I accessibility assay was
performed with A549 cells treated for 10 minutes with DMSO or DEX
(0.5 mM). DNase I digestion lasted 5 min, and fragments were analyzed
by qPCR using the same primers (p1-p6) used for ChIP qPCR in
Figure 1B. 50 ng DNA was used per well for qPCR. Results are shown as
a percent increase of DNase I accessibility relative to DNA not digested
by DNase I, where 100% accessibility represents a complete digestion of
DNA. Data represent the SEM of percentage increase (DNaseI-cut cells
divided by uncut cells) from at least four experiments. B Nucleosome
positioning was analyzed with micrococcal nuclease (MNase) digestion
for the 21550 to 21050 region of the DUSP1 promoter. A549 cells were
treated for 10 minutes with DMSO or DEX (0.5 mM) before digestion
with MNase for 10 min. qPCR was performed with primers annealing
approximately every 50 bp. Results are shown as the amount of each
genomic fragment in the MNase sample, calculated based on a
standard curve from genomic DNA titrations with each primer set. C
Three potential nucleosomal regions are located at approximately
21500 to 21350 (nucleosome 1), 21350 to 21200 (nucleosome 2), and
21200 to 21050 (nucleosome 3) of the human DUSP1 gene. GLS2 is
located between nuclesomes 1 and 2.
doi:10.1371/journal.pone.0013754.g003
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(Fig. S2A, and DEX/DMSO fold induction in Fig. 4A).
Conversely, DEX treatment potentiated AcH4/H4 levels in the
genomic region from 21815 to 2543, but had no effect in the
region from 2160 to +215 (Fig. S2B and Fig. 4B).
Next, we wished to determine the histone acetyltransferase
(HAT) that acetylates H3 and H4 at the DUSP1 gene. Several
coactivators for GR, including GCN5, PCAF, CBP/p300, have
been shown to contain histone acetyltransferase (HAT) activity.
We reason that if a coactivator is directly involved in glucocor-
ticoid-activated DUSP1 gene transcription, it should be present on
the DUSP1 promoter upon DEX treatment. To determine which
of these factors are directly involved in glucocorticoid-activated
DUSP1 gene transcription, we treated A549 cells with DMSO or
DEX for 10 minutes, then ChIPed for GCN5, PCAF, CBP and
p300 in the areas surrounding the DUSP1 GRE. Of these, p300
was present before treatment with glucocorticoids (relative to ChIP
with IgG control), with levels increasing approximately 16 fold
after only 10 minutes of DEX treatment (Fig. 5A). In contrast,
CBP was absent without treatment, but was enriched approxi-
mately 1.9 fold with 10 minutes of DEX treatment (Fig. 5A). We
used RNA interference (RNAi) to reduce the expression of p300
and CBP in A549 cells (Fig. 5B), then tested whether this
compromised the ability of DEX to stimulate the expression of the
DUSP1 gene (Fig. 5C). Compared to cells transfected with
negative control siRNA, p300 knockdown resulted in approxi-
mately a two-fold increase of basal expression of DUSP1 gene (Fig.
S3). However, the ability of DEX to induce DUSP1 gene
expression was decreased approximately 40% (Fig. 5C). These
results indicate that under basal conditions, p300 inhibits DUSP1
gene expression, while upon DEX stimulation it contributes to
induction of DUSP1 gene expression. CBP RNAi affected neither
basal nor DEX-stimulated expression of DUSP1 gene (Fig. S3 and
Fig. 5C).
p300 is involved in glucocorticoid-induced
hyperacetylation of H3 in genomic regions surrounding
GRE
We used RNAi to decrease the expression of p300 to further
investigate its role in DEX-induced histone hyperacetylation. As
shown in Fig. 6A, the levels of AcH3/H3 in p300 RNAi cells were
similar to those of control RNAi cells before DEX treatment.
However, while a 10 minute DEX treatment significantly in-
duced AcH3/H3 levels in controlR N A ic e l l s ,t h ea b i l i t yo fD E X
to increase AcH3/H3 levels was markedly compromised in p300
knockdown cells (Fig. 6A). These results suggest that p300 is
involved in DEX-induced histone H3 hyperacetylation surround-
ing the DUSP1 GRE,though it does not participate in acetylation
of H3 before DEX treatment. Interestingly, AcH4/H4 levels in
p300 RNAi cells were similar to those of control RNAi cells
before and after 10 min DEX treatment (Fig. 6B). Thus,
decreasing p300 expression does not affect DEX-induced histone
H4 hyperacetylation.
To further confirm the importance of p300-induced histone
acetylation in DEX-induced DUSP1 gene transcription, we
compared the ability of wild type (WT) p300 and a p300 mutant
with reduced histone acetyltransferase (HAT) activity
(p300DHAT) to coactivate DEX-induced pDUSP1 reporter gene
expression (Fig. 6C). We found that overexpression of p300WT
reduced basal reporter activity by 47% (Fig. S4). These data
support our p300 RNAi results showing that p300 has a repressive
role in basal DUSP1 gene expression. In contrast to p300WT,
overexpression of p300DHAT reduced basal reporter activity
approximately 24% (Fig. S4). Overexpression of p300WT
potentiated the DEX-induced reporter gene expression response
from 5.8 fold to 9.5 fold (Fig. 6C), whereas overexpression of
p300DHAT increased the DEX response to 7.8 fold (Fig. 6C).
These data confirm that in response to glucocorticoids, the
mechanism of p300 coactivation of DUSP1 gene transcription
involves, but is not limited to, p300 HAT activity.
Finally, we performed ChIP-reChIP experiments to determine
if p300 and GR are recruited to the same genomic region of
DUSP1. GR antibodies were first used to pull down GR-
associated DNA fragments. Antibodies against p300 were then
used to isolate GR-associated DNA fragments that also associate
with p300. Compared to ChIP-reChIP using IgG control
antibodies, ChIP-reChIP using GR and then p300 showed
significant enrichment of the DUSP1 GRE (23 fold, Fig. 6D).
These results suggest that GR and p300 are in the same protein
complex recruited to the DUSP1 GRE.
Figure 4. Glucocorticoids increased histone H3 and H4
acetylation of the DUSP1 gene promoter. A A549 cells were
treated with DMSO or DEX (0.5 mM) for 10 min, and ChIPs were
performed with antibodies against both total histone H3 and multiple
acetylated lysines on histone H3 (AcH3). qPCR was performed with the
same six primers used for ChIP qPCR in Figure 1B. AcH3 data was
normalized to total H3 values and represents the SEM of the fold
induction (DEX-treated cells divided by DMSO-treated cells) from at
least four experiments. B Identical experiments and calculations as in A,
with ChIP antibodies against both total histone H4 and multiple
acetylated lysines on histone H4 (AcH4).
doi:10.1371/journal.pone.0013754.g004
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Multiple mechanisms contribute to the anti-inflammatory
effects of glucocorticoids. One of them is the ability of
glucocorticoids to induce the transcription of DUSP1. Thus,
understanding the regulatory mechanism of glucocorticoid-acti-
vated DUSP1 gene transcription is vital for future therapeutic
interventions against inflammatory diseases. In this study, we
systematically investigated the mechanisms of GR-regulated
DUSP1 gene transcription. First, we determined that GR regulates
the expression of DUSP1 through transcriptional initiation
(Fig. 1A); then, we identified the GRE at the human DUSP1
promoter that is responsible for this regulation (Fig. 1B, 1C). The
GRE appeared to be in organized nucleosomal structures, within
which GR is bound at a consensus GR binding site (GLS2) at the
GRE (Fig. 2 and Fig. 3). We also showed that the induction of
DUSP1 gene transcription by glucocorticoids involves the opening
up of chromatin structure in the DUSP1 promoter region
corresponding with changes in the nucleosomal status (Fig. 3).
While histone H3 and H4 of the DUSP1 promoter are already
acetylated in the basal state, glucocorticoids further increased
acetylated histone H3 and H4 levels (Fig. S2 and Fig. 4). Finally,
we showed that p300 acts as a transcriptional coactivator for GR
in the induction of DUSP1 gene transcription (Fig. 5 and Fig. 6).
GR and p300 appear to be in the same protein complex recruited
to the DUSP1 GRE (Fig. 6D), and reducing the expression of p300
in cells specifically decreased glucocorticoid-stimulated histone H3
acetylation (Fig. 6A). Overall, these observations provide a solid
foundation that will allow us to further dissect this important
transcriptional regulatory mechanism.
A recent study using genomic conservation analyses identified
multiple GREs upstream of the human DUSP1 gene [31]. These
GREs include the one reported here, located ,1.3 kb upstream of
the TSS. In a reporter gene that contains this GRE and another
located 4.6 kb upstream of the TSS, Tchen et al. showed that the
mutation of either GRE reduces hormonal response by approx-
imately 50%. Thus, both GREs play a role in glucocorticoid-
regulated DUSP1 gene transcription. This confirms the impor-
tance of our studies on the role of the presently characterized GRE
in overall transcriptional activation of the DUSP1 gene. The
locations of other GREs identified by Tchen et al. are far away
from the TSS (29, 28 and 24 kb), and genome-wide analysis of GR
binding regions indeed reveals that many potential GREs are
located far away from the TSS [32,33]. However, the importance
of these long-range GREs in DUSP1 gene regulation is unclear at
the moment, as these GREs have not been studied in their natural
configuration. Future studies should address these questions.
In addition to GLS2, we identified three other GLS elements
that may play accessory roles in the regulation of DUSP1 gene
transcription. Interestingly, only one of these three is required for a
complete glucocorticoid response, and any of these three can play
the accessory role. It is unclear whether the mechanisms governing
the functional interactions between GLS2 and GLS1, 3, or 4 are
the same. This will require detailed studies of the role of these
accessory elements in glucocorticoid response. At present, we
cannot be sure if they directly associate with GR. It is possible that
GLS2, which fits the consensus sequence of a canonical GR
binding site, serves as an essential site for the binding of GR while
the other GLS elements, which are more divergent, can only bind
to the receptor when GR:GLS2 interacts. Alternatively, these GLS
elements may bind to other transcriptional regulators. The
requirement of functional interactions between GR and other
DNA-binding transcriptional regulators to confer a complete
glucocorticoid response has been previously reported. These
Figure 5. p300 is a transcriptional coactivator for GR-regulated
DUSP1 gene transcription. A Glucocorticoid treatment increased
the level of p300 and CBP at the DUSP1 GLS2 region. A549 cells were
treated with DMSO or DEX (0.5 mM) for 10 min, and ChIP was
performed with antibodies against p300, CBP and IgG (control). Data
is shown from qPCR analyses with primers specific to the DUSP1 GLS2.
B RNAi knockdown causes substantial reduction of p300 protein and
CBP protein. A549 cells reverse transfected with p300, CBP or scramble
siRNA were harvested 48 h post-transfection, then probed by Western
blot using an antibody against p300 or CBP, with b-actin as a loading
control. C RNAi against p300 but not CBP decreased DEX-induced
DUSP1 gene expression. p300, CBP or scramble (control) siRNA was
transfected into A549 cells. 48 h post-transfection, cells were treated
with DMSO or DEX (0.5 mM) for 5 h. Total RNA was isolated and
converted to cDNA. qPCR was used to monitor the expression of DUSP1
gene. The expression of Rpl19 gene was used as an internal control.
Data represents the SEM of DEX-induced DUSP1 gene expression (DEX-
treated cells divided by DMSO-treated cells), as a percent of the control
siRNA response from at least three experiments.
doi:10.1371/journal.pone.0013754.g005
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[34,35,36,37], rat tyrosine aminotransferase (TAT) [38,39] and rat
glucose-6-phosphatase [40] genes. Thus, these GLS elements
could add another layer of control to the regulatory mechanisms of
GR-activated DUSP1 gene expression. Notably, within the GRE
identified here, there is a CCAAT enhancer binding protein (C/
EBP) site (21312 and 21305) [41], located adjacent to the GR
binding sequence (21337 and 21323). This configuration of the
DUSP1 GRE is reminiscent of glucocorticoid-activated rat a1-
acid glycoprotein (AGP) in hepatocytes. The rat AGP gene GRE is
a composite response element that contains both GR and C/EBPb
binding sites – requiring both for synergistic activation [42,43].
Intriguingly, transcriptional synergism is still observed even when
one of the two factors lacked either its DNA-binding or
transcriptional-activation function. Thus, a direct protein-protein
interaction between these two distinct transcription factors is
probably required to regulate the rat AGP gene [42,43].
Supporting this mechanism, overexpression of a GR mutant
defective in DNA binding still potentiates the glucocorticoid
response in DUSP1 gene expression [41]. The functional
interaction between GR and C/EBPb has also been reported in
the regulation of other glucocorticoid target genes, such as
phosphoenolpyruvate carboxykinase (PEPCK) and b-casein
[44,45]. The role of C/EBP binding site in glucocorticoid-
activated DUSP1 gene transcription merits future studies.
Chromatin structure plays a critical role in the regulation of
gene transcription. Based on our findings from DNase I
accessibility experiments, the DUSP1 genomic region up to
,2 kb upstream of the TSS is already opened up prior to
treatment with glucocorticoids (Fig. 3A). Glucocorticoid treatment
further increases this region’s DNase I accessibility except in the
area from 2160 to 264. The results from MNase experiments
indicate that nucleosomes 1 and 2 are likely remodeled, increasing
the accessibility of DNase I to chromatin in this region. Previous
studies have shown that transcriptional activation of several
glucocorticoid target genes requires the SWI/SNF chromatin
remodeling complex [46,47]. When we knocked down the
expression of Brm, an ATPase subunit of SWI/SNF, in A549
cells, the ability of glucocorticoids to stimulate several of their
target genes was reduced – intriguingly, DUSP1 escapes this
requirement for Brm (data not shown). This suggests that Brg1,
another ATPase component of the SWI/SNF complex, may
compensate for the loss of Brm in A549 cells. Alternatively, it is
possible that chromatin remodeling complexes other than SWI/
SNF are involved in glucocorticoid-regulated DUSP1 gene
transcription. We are currently investigating these possibilities.
The analyses of histone acetylation status in the DUSP1 gene
promoter showed that the genomic region up to 2 kb upstream of
the TSS is already acetylated in its basal state. These results are in
Figure 6. p300 contributes to hyperacetylation of H3 but not
H4 in DUSP1 GRE-surrounding region. A A549 cells reverse
transfected with p300 or scramble (control) RNAi were treated 48 h
post-transfection with DMSO or DEX (0.5 mM) for 10 min. ChIPs were
performed for AcH3 and H3 as described in Figure 4A, and B for AcH4
and H4 as described in Figure 4B. RNAi knockdown of p300 decreases
DEX-induced hyperacetylation of H3 but not H4. Data represent the
SEM of fold change relative to IgG ChIP from at least four experiments.
C pCI, pCI-p300 wild type (WT), or pCI-p300DHAT mutant was co-
transfected with pDUSP1 along with an expression vector for human GR
into A549 cells. Cells were treated with DMSO or DEX as described in
Figure 1C. Luciferase assay data represents the SEM of the fold
induction of luciferase activity (DEX-treated cells divided by DMSO-
treated cells) from at least five experiments. *p300WT caused significant
induction from pCI control (student t-test, p,0.0001). ** p300DHAT
mutation caused significant reduction from p300WT response (student
t-test, p=0.01). D ChIP-reChIP was performe with GR antibody followed
by p300 antibody to isolate fragments bound to both GR and p300.
Fragments were analyzed by qPCR with primers corresponding to GLS2.
Data represent the SEM of the fold enrichment (DMSO- or DEX-treated




PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13754agreement with the DNase I accessibility findings discussed above
and are not surprising, as DUSP1 gene expression is not silent in
the absence of glucocorticoid treatment. The fact that glucocor-
ticoid treatment further increases the acetylation status of histone
H3 and H4 indicates that HAT(s) are correlated with the
glucocorticoid response on DUSP1 gene expression. We found
two HATs, p300 and CBP, whose recruitment to the DUSP1
GRE is increased upon DEX treatment. RNAi knockdown of CBP
fails to affect basal or glucocorticoid-stimulated DUSP1 gene
expression, both of which are affected by p300 RNAi (Fig. 5C and
Fig. S3). Although p300 and CBP frequently exert redundant
functions in vitro, their roles in DEX-activated DUSP1 gene
transcription may be distinct. Alternatively, the CBP protein
remaining after RNAi knockdown may be sufficient to maintain
normal effects of CBP on DUSP1 gene expression. While further
investigation is necessary to examine these possibilities, our current
study better illuminates the role of p300.
We found that p300 is present in the DUSP1 gene promoter in
the basal state, and glucocorticoid treatment further augments its
occupancy. It is possible that p300 is recruited to the promoter
region near the DUSP1 GRE through existing DNA-binding
transcriptional regulators. Upon glucocorticoid treatment, GR
binds to the GRE and further recruits p300 to the GRE.
Interestingly, the results from our RNAi experiments indicate that
p300 has dual roles on DUSP1 gene expression. RNAi knockdown
of p300 increases basal gene expression of DUSP1, but also limits
the ability of glucocorticoids to potentiate DUSP1 gene transcrip-
tion. Thus, p300 likely acts as a corepressor for basal DUSP1
expression, but as a coactivator for GR-stimulated DUSP1 gene
transcription. Other results in this report support this model.
Supporting the corepressor role, p300 overexpression reduced the
activity of a reporter gene containing the 21672 to 2959 region of
DUSP1 gene. This suggests that the element(s) responsible for
repressive effects of p300 is located in this genomic region.
Notably, it has been reported that p300 can reduce the
transcriptional activity of certain DNA-binding transcription
factors [48,49], and it will be interesting to identify these element(s)
and their associated proteins in future studies. Supporting the
coactivator role of p300, overexpression of p300 increased DEX-
induced reporter activity from 5.8 to 9.5 fold, whereas a p300
mutant lacking HAT activity only stimulated the reporter activity
to 7.8 fold. Together, these results indicate that the HAT activity
of p300 plays a role in DEX-induced DUSP1 gene expression.
RNAi knockdown of p300 in A549 cells abolished DEX-induced
H3 acetylation, which further supports the role of HAT activity in
p300 but does not exclude other potential mechanisms of p300
activity. Finally, ChIP-reChIP experiments showed GR and p300
are in the same protein complex that associates with the DUSP1
GRE, which also supports the role of p300 as a GR coactivator.
Glucocorticoids are an essential tool in combating inflammatory
disorders, however their use is limited by multiple serious side
effects. There is a conception that glucocorticoids’ anti-inflamma-
tory effects are attributed to GR-regulated transcriptional
repression, while the side effects reflect transcriptional activation
by GR. However, recent studies clearly demonstrate the
importance of glucocorticoid-activated DUSP1 gene expression
in mediating the anti-inflammatory effects of glucocorticoids.
Thus, an important topic in glucocorticoid pharmacology will be
how to dissociate transcriptional activation of GR-induced anti-
inflammatory actions from the undesired side effects. To do this, it
is critical to identify the specific components of the mechanisms
governing GR-activated transcription of DUSP1 and other genes
involved in the induction of unwanted side effects.
Supporting Information
Figure S1 DNaseI accessibility of a-fetoprotein gene in response
to glucocorticoids. An example of a gene whose chromatin
structure is not opened up in response to glucocorticoids. a-
fetoprotein (AFP) gene schematic shows the location of three
primers used (black boxes labeled A1–A3) for qPCR analyses. The
regions of the AFP gene (relative to the TSS) amplified by these
primers are: A1 (2729 to 2652), A2 (2405 to 2324), and A3
(2183 to 299). DNase I accessibility assay and calculations were
performed as described in Figure 3. Data represent the SEM of
percentage increase (DNaseI-cut cells divided by uncut cells) from
at least three experiments.
Found at: doi:10.1371/journal.pone.0013754.s001 (0.29 MB TIF)
Figure S2 Basal and glucocorticoid-induced histone H3 and H4
acetylation of the DUSP1 gene promoter. A AcH3/H3 ChIP
experiments presented in Figure 4A, with results shown relative to
IgG ChIP. B AcH4/H4 ChIP experiments presented in Figure 4B,
with results shown relative to IgG ChIP. The data represent the
SEM of the fold induction (DEX-treated cells divided by DMSO-
treated cells) from at least four experiments.
Found at: doi:10.1371/journal.pone.0013754.s002 (0.45 MB TIF)
Figure S3 Effects of p300 and CBP siRNA on basal DUSP1
gene expression. RNAi knockdown experiments presented in
Figure 5C, showing RNAi against p300 and CBP increased basal
(DMSO-treated) DUSP1 gene expression relative to scramble
(control). Data represent the SEM of fold induction (p300 or CBP
siRNA divided by scramble control) from at least three
experiments.
Found at: doi:10.1371/journal.pone.0013754.s003 (0.16 MB TIF)
Figure S4 Effects of p300WT and p300DHAT overexpression
on basal activity of pDUSP1 reporter gene. pDUSP1 reporter
assay presented in Figure 6C, showing both pCI-p300WT and
pCI-p300DHAT decreased basal (DMSO-treated) reporter activ-
ity. Data represent the SEM of fold induction (pCI-p300WT or
pCI-p300DHAT divided by pCI control) from five experiments.
Found at: doi:10.1371/journal.pone.0013754.s004 (0.15 MB TIF)
Table S1 Primers.
Found at: doi:10.1371/journal.pone.0013754.s005 (0.04 MB
DOC)
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